Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

Summary

Background

Targeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases. We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases.

Methods

TRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAF^V600 wild-type cohort and a BRAF^V600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland. Eligible patients were aged 18 years or older with previously untreated metastatic melanoma, CNS metastases of 5 mm or larger in at least one dimension, and an Eastern Cooperative Oncology Group performance status of 2 or less. Patients in the BRAF^V600 wild-type cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral cobimetinib (60 mg once daily, days 1–21). Patients in the BRAF^V600 mutation-positive cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral vemurafenib (720 mg twice daily) plus oral cobimetinib (60 mg once daily, days 1–21); atezolizumab was withheld in cycle 1. Treatment was continued until progression, toxicity, or death. The primary outcome was intracranial objective response rate confirmed by assessments at least 4 weeks apart, as assessed by independent review committee (IRC) using modified Response Evaluation Criteria in Solid Tumours version 1.1. Because of early closure of the BRAF^V600 wild-type cohort, the primary endpoint of intracranial objective response rate by IRC assessment was not done in this cohort; intracranial objective response rate by investigator assessment was reported instead. Efficacy and safety were analysed in all patients who received at least one dose of study medication. This trial is closed to enrolment and is registered with ClinicalTrials.gov, NCT03625141.

Findings

Between Dec 13, 2018, and Dec 7, 2020, 65 patients were enrolled in the BRAF^V600 mutation-positive cohort; the BRAF^V600 wild-type cohort was closed early after enrolment of 15 patients. Median follow-up was 9·7 months (IQR 6·3–15·0) for the BRAF^V600 mutation-positive cohort and 6·2 months (3·5–23·0) for the BRAF^V600 wild-type cohort. Intracranial objective response rate was 42% (95% CI 29–54) by IRC assessment in the BRAF^V600 mutation-positive cohort and 27% (95% CI 8–55) by investigator assessment in the BRAF^V600 wild-type cohort. Treatment-related grade 3 or worse adverse events occurred in 41 (68%) of 60 patients who received atezolizumab plus vemurafenib plus cobimetinib in the BRAF^V600 mutation-positive cohort, the most common of which were lipase increased (15 [25%] of 60 patients) and blood creatine phosphokinase increased (ten [17%]). Eight (53%) of 15 patients treated with atezolizumab plus cobimetinib in the BRAF^V600 wild-type cohort had treatment-related grade 3 or worse adverse events, most commonly anaemia (two [13%]) and dermatitis acneiform (two [13%]). Treatment-related serious adverse events occurred in 14 (23%) of 60 patients in the BRAF^V600 mutation-positive cohort and two (13%) of 15 in the BRAF^V600 wild-type cohort. One death in the BRAF^V600 mutation-positive cohort (limbic encephalitis) was considered to be related to atezolizumab treatment.

Interpretation

Adding atezolizumab to vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAF^V600-mutated melanoma with CNS metastases.

Funding

F Hoffmann-La Roche.